10x Genomics appoints Sarah A. Teichmann to Board of Directors

10x Genomics, Inc.

Effective July 10, 2024; Class II director with term expiring at 2027 annual meeting.
Teichmann is Chair in Stem Cell Medicine at University of Cambridge and co-chair of Human Cell Atlas.
She receives $55,000 annual cash retainer plus initial RSU grant valued at $400,000.
Annual RSU grant of $215,000 on annual meeting date; both grants vest over time with continued service.
Also serves as VP at GSK and CSO at EnsoCell Therapeutics; brings genomics and leadership expertise.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sarah A. Teichmann

Director

TXG · 10x Genomics, Inc.

Effective: 2024-07-10
Filed: July 11, 2024, 7:59 PM ET

On July 10, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Sarah A. Teichmann to the Board of Directors as a Class II director effective immediately with a term expiring at the Company's 2027 annual meeting of stockholders or until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sarah A. Teichmann was appointed as Director at 10x Genomics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 10, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Sarah A. Teichmann to the Board of Directors as a Class II director effective immediately with a term expiring at the Company's 2027 annual meeting of stockholders or until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal.

View on SEC.gov

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001770787-24-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.